Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells $227,800.65 in Stock

Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 12,551 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $18.15, for a total value of $227,800.65. Following the completion of the sale, the chief executive officer now owns 282,775 shares of the company’s stock, valued at approximately $5,132,366.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ NKTR opened at $17.01 on Thursday. The company has a debt-to-equity ratio of 0.22, a current ratio of 14.09 and a quick ratio of 13.97. Nektar Therapeutics has a twelve month low of $16.56 and a twelve month high of $69.76. The business’s fifty day moving average is $28.62 and its 200 day moving average is $33.70.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.17. Nektar Therapeutics had a negative return on equity of 25.25% and a negative net margin of 354.90%. The company had revenue of $23.32 million for the quarter, compared to the consensus estimate of $26.65 million. During the same quarter last year, the business posted $5.33 EPS. Nektar Therapeutics’s revenue for the quarter was down 97.9% on a year-over-year basis. Equities research analysts forecast that Nektar Therapeutics will post -2.93 EPS for the current year.



NKTR has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “hold” rating on shares of Nektar Therapeutics in a report on Tuesday, August 13th. BidaskClub downgraded Nektar Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 16th. William Blair reiterated a “buy” rating on shares of Nektar Therapeutics in a report on Friday, August 9th. Mizuho downgraded Nektar Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $79.00 to $21.00 in a report on Friday, August 9th. Finally, JPMorgan Chase & Co. downgraded Nektar Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $62.00 to $33.00 in a report on Friday, August 9th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Nektar Therapeutics presently has a consensus rating of “Hold” and an average price target of $49.15.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. boosted its holdings in shares of Nektar Therapeutics by 150.2% during the 1st quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 479 shares in the last quarter. Quantamental Technologies LLC acquired a new position in Nektar Therapeutics during the 1st quarter worth about $27,000. Capital Investment Advisory Services LLC lifted its holdings in Nektar Therapeutics by 1,566.7% during the 2nd quarter. Capital Investment Advisory Services LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 940 shares during the period. Kavar Capital Partners LLC acquired a new position in Nektar Therapeutics during the 2nd quarter worth about $44,000. Finally, Gemmer Asset Management LLC lifted its holdings in Nektar Therapeutics by 476.8% during the 2nd quarter. Gemmer Asset Management LLC now owns 1,390 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 1,149 shares during the period. 91.23% of the stock is currently owned by institutional investors.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

See Also: How do analysts define an oversold condition?

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.